NEW YORK – T2 Biosystems announced Wednesday it has regained compliance with the Nasdaq's minimum bid price continued listing requirement.
In April, the company was notified it wasn't in compliance with the requirement because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days.